GlobeNewswire by notified

Photocat strengthens its position in Switzerland within Sustainable Solutions through partnership with Hydag AG


October 31st 2023

Photocat strengthens its position in Switzerland within Sustainable Solutions through partnership with Hydag AG

Roskilde, Denmark. October 31st, 2023 – Photocat, a global leader and innovator of sustainable solutions, is proud to announce a strategic commercial partnership with Hydag AG, a Swiss leader in techno-chemical technologies. This partnership signals a significant step forward in Photocat's mission to revolutionize the world with sustainable and eco-friendly solutions.

Key Partnership Highlights:

  • Expanding Photocat's marketplace for CMA Suite of Products: Road salt has been used for many years with acceptance of the significant negative side effects like corrosion, negative effect of water and plants. Photocat solution has changed this completely to offer both significant economic advantages as well as significant advantages in reduction of PM 1, 2.5 and 10 in the air bringing a much more desirable health benefit to citizens. As part of this collaboration, Photocat's cutting-edge CMA suite of de-icing products will be at the forefront of enhancing environmental performance across various sectors. These products are designed to cater to a wide range of applications and stand out due to its documented benefits over traditional road salt.

  • Harnessing Photocatalytic Technologies: Photocat's suite of photocatalytic technologies will play a pivotal role in this partnership. These innovative technologies utilize the power of light and photocatalysis to break down pollutants (NOx) as well as Volatile Organic Components (VOCs) and hence ensuring cleaner and more sustainable environments in metropolitan and densely populated areas.

  • Initial Order of 18 Pallets for Commercialization: Hydag AG has placed an initial order for 18 pallets of Photocat's CMA suite of products, signifying a strong commitment to introducing these innovative solutions to the market. This order represents the beginning of a transformative journey towards providing effective and eco-friendly de-icing solutions to the Swiss market.

  • Financial impact: Our partnership with Hydag AG will not influence the financial performance of 2023. The accumulated value over the 3-year contractual period may reach up to 3 million DKK.

A Strong Commitment to Sustainability:

Both Photocat and Hydag AG share a deep commitment to sustainable practices and technologies. This partnership allows the synergy of expertise and innovation to drive change in various industries and for various types of stakeholders – promoting cleaner air, more energy-efficient de-icing processes, and self-sustaining environments.

Flavio Gregori (Chairman and CEO of Hydag AG) and Jesper Elsgaard (CBO of Photocat A/S) are enthusiastic about the possibilities this partnership holds and are fully committed to leveraging their respective strengths to create a brighter and more sustainable future in Switzerland.

A Glimpse into the Future:

This partnership is set to accelerate the adoption of innovative solutions that enhance sustainability and reduce the environmental footprint. By combining Photocat's CMA suite of products and photocatalytic technologies with Hydag AG's expertise, we are confident in the positive impact we can make on the environmental health for Swiss inhabitants.

For further information, please contact:
Jesper Elsgaard
Chief Business Officer
Photocat A/S
Tel: +45 5121 7651

About Photocat A/S:
Photocat is a leading innovator in sustainable solutions, dedicated to harnessing the power of photocatalysis to create a cleaner and more sustainable world as well as eco-friendly and efficient de-icing and dust-suppression solutions. With a focus on cutting-edge technologies and partnerships, Photocat is at the forefront of environmental innovation. Photocat’s shares are listed on Nasdaq Stockholm, First North with the ticker symbol PCAT. The company’s Certified Advisor is Mangold Fondkommission AB.

About Hydag AG:
Hydag AG is a Swiss leader for techno-chemical products used for the prevention of scale and corrosion in steam generators and district heating systems. Their commitment to deliver innovative products and technologies aligns seamlessly with Photocat's mission to advance sustainability and reduce environmental impact.

Photocat A/S (publ) l Langebjerg 4 DK-4000 Roskilde l Tel: +45 7022 5055 l


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Dassault Aviation Wins Choiseul “Strategic Company” Award29.11.2023 10:21:57 CET | Press release

Dassault Aviation Wins Choiseul “Strategic Company” Award (Saint-Cloud, November 29, 2023) – Dassault Aviation is particularly proud to have received the 2023 Strategic Company Award as part of the Institut Choiseul’s Sovereignty Initiative. The institute believes that strategic companies represent one of the many facets of national strength. Award recipients are known for their capacity to effectively mobilize resources and know-how, and to provide solutions that meet national priorities. They are a cornerstone of French strategic heritage. Dassault Aviation is an industrial architect and complex systems integrator, a developer of strategic technologies, a major national exporter, a core shareholder of the Thales Group and a vital player in an industrial landscape that includes hundreds of business and service partners. The company is at the core of the French sovereign defense ecosystem. Dassault Aviation is also the only non-American company that manufactures high-end business jets.

Company announcement no 17/2023 Interim Report Q3 202329.11.2023 10:20:00 CET | Press release

Interim Report Q3 2023 EBITDA fixed herd prices (FHP) for Q3 2023 increased to 13.663 mEUR (Q3 2022: 10.463 kEUR), corresponding to an EBITDA margin FHP of 36.3% (Q3 2022: 32.5%). The quarterly EBITDA in Q3 2023 increased by 3.201 kEUR (compared to Q3 2022). Nevertheless, this consist of many parts this quarter: Russia harvest negative with 2,7 mEUR (from 4,1 to 1,5 mEUR) whereas remaining Russian business compensate positive with 3,0 mEUR partly due to FX (cost in EUR lower), Lithuania negative effects from one-off subsidy in Q3 2022 (2,5 mEUR), but combined sales/feed with positive effect of 4.9 mEUR and lower cost levels with 0.5 mEUR driven by utilities. Sales prices combined down, as they in Q3 2023 were 1.59 EUR/kg live weight, down from 1.62 EUR/kg Q2 2022 equal to EUR 0,8m, but EURRUB effects this picture highly as Lithuanian sales prices in EUR is up 23% and Russian in RUB is up 13%. Feed prices in Q3 2023 were 261 EUR/T (compared to 332 EUR/T Q3 2022). End September 2023 on h

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®29.11.2023 10:00:00 CET | Press release

The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The study, which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects, met its primary endpoints. “These results demonstrate the strength of our platform approach to biosimilars development and manufacture, combining a well-designed and executed clinical study with the design of a high-quality manufacturing process and strong analytical capabilities,” said Joseph McClellan, Chief Scientific Officer. “As we progress more biosimilar candidates through clinical development and approval, w